Pharmacogenetic markers to predict the clinical response to methotrexate in south Indian Tamil patients with psoriasis

Nestle FO, Kaplan DH, Barker J (2009) Psoriasis. N Engl J Med 361:496–509 Bowcock AM, Krueger JG (2005) Getting under the skin: the immunogenetics of psoriasis. Nat Rev Immunol 5:699–711 Elder JT, Nair RP, Henseler T et al (2001) The genetics of psoriasis 2001. The odyssey continues. Arch Dermatol 137:1447–1454 Langley RG, Krueger GG, Griffiths CE (2005) Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis 64(suppl 2):ii18–ii23 Menter A, Gottlieb A, Feldman SR et al (2008) Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 58:826–850 Lebwohl M (2005) A clinician’s paradigm in the treatment of psoriasis. J Am Acad Dermatol 53:S59–S69 Menter A, Griffiths CEM (2007) Current and future management of psoriasis. Lancet 370:272–284 Ranganathan P (2012) The challenges of methotrexate pharmacogenetics in rheumatoid arthritis. Pharmacogenomics 13:377 Indhumathi S, Rajappa M, Chandrashekar L, Ananthanarayanan PH, Thappa DM, Negi VS (2016) Investigation of association of the IL-12B and IL-23R genetic variations with psoriatic risk in a South Indian Tamil cohort. Hum Immunol 77:54–62 Griffiths CE, Christophers E, Barker JN et al (2007) A classification of psoriasis vulgaris according to phenotype. Br J Dermatol 156:258–262 Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, CASPAR Study Group (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54:2665–2673 Langley RG, Ellis CN (2004) Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment and Lattice System Physician’s Global Assessment. J Am Acad Dermatol 51:563–569 Baker C, Mack A, Cooper A, Fischer G, Shumack S, Sidhu S et al (2013) Treatment goals for moderate to severe psoriasis: an Australian consensus. Australas J Dermatol 54:148–154 Miller SA, Dykes DD, Polesky HF (1988) Simple salting out procedure for extracting DNA from human nucleated cells. Nucl Acids Res 16:1215 Rebala K, Szczerkowska-Dobosz A, Niespodziana K, Wysocka J (2010) Simple and rapid screening for HLA-Cw6 in Polish patients with psoriasis. Clin Exp Dermatol 35:431–436 Perrey C, Turner SJ, Pravica V, Howell WM, Hutchinson IV (1999) ARMS-PCR methodologies to determine IL-10, TNF-α, TNF-β and TGF-β1 gene polymorphisms. Transpl Immunol 7:127–128 Fichna M, Zurawek M, Fichna P, Suchanek IZ, Januszkiewicz D, Nowak J (2013) Polymorphic variant at the IL-2 region is associated with type 1 diabetes and may affect serum levels of interleukin-2. Mol Biol Rep 40:6957–6963 Kuhn A, Ruland V, Patsinakidis N, Luger TA (2010) Use of methotrexate in patients with psoriasis. Clin Exp Rheumatol 28:S138–S144 Cronstein BN (2005) Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev 57:163–172 Julia M, Guilabert A, Lozano F et al (2013) The role of Fcc receptor polymorphisms in the response to anti-tumor necrosis factor therapy in psoriasis: a pharmacogenetic study. JAMA Dermatol 149:1033–1039 Gedebjerg A, Johansen C, Kragballe K, Iversen L (2013) IL-20, IL-21 and p40: potential biomarkers of treatment response for ustekinumab. Acta DermVenereol 93:150–155 Tejasvi T, Stuart PE, Chandran V et al (2012) TNFAIP3 gene polymorphisms are associated with response to TNF blockade in psoriasis. J Invest Dermatol. 132:593–600 Vasilopoulos Y, Manolika M, Zafiriou E et al (2012) Pharmacogenetic analysis of TNF, TNFRSF1A, and TNFRSF1B gene polymorphisms and prediction of response to anti-TNF therapy in psoriasis patients in the Greek population. Mol Diagn Ther 16:29–34 Elder JT, Bruce AT, Gudjonsson JE et al (2010) Molecular dissection of psoriasis: integrating genetics and biology. J Invest Dermatol. 130:1213–1226 Indhumathi S, Rajappa M, Chandrashekar L, Ananthanarayanan PH, Thappa DM, Negi VS (2016) The HLA-C*06 allele as a possible genetic predisposing factor to psoriasis in south Indian Tamils. Arch Dermatol Res 308:193–199 Indhumathi S, Rajappa M, Chandrashekar L, Ananthanarayanan PH, Thappa DM, Negi VS (2015) TNFAIP3 and TNIP1 polymorphisms confer psoriasis risk in South Indian Tamils. Br J Biomed Sci 72:168–173 Indhumathi S, Rajappa M, Chandrashekar L, Ananthanarayanan PH, Thappa DM, Negi VS (2017) T helper-2 cytokine/regulatory T-cell gene polymorphisms and their relation with risk of psoriasis in a South Indian Tamil cohort. Hum Immunol 78:209–215 Talamonti M, Botti E, Galluzzo M et al (2013) Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab. Br J Dermatol 169:458–463 Chiu HY, Wang TS, Chan CC, Cheng YP, Lin SJ, Tsai TF (2014) Human leucocyte antigen-Cw6 as a predictor for clinical response to ustekinumab, an interleukin-12/23 blocker, in Chinese patients with psoriasis: a retrospective analysis. Br J Dermatol 171:1181–1188 Warren RB, Smith RL, Campalani E et al (2008) Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis. J Invest Dermatol 128:1925–1929 Elango T, Dayalan H, Gnanaraj P, Malligarjun H, Subramanian S (2014) Impact of methotrexate on oxidative stress and apoptosis markers in psoriatic patients. Clin Exp Med 14:431–437 Gerards AH, de Lathouder S, de Groot ER, Dijkmans BA, Aarden LA (2003) Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis. Rheumatology (Oxford) 42:1189–1196